Erectile function after stereotactic body radiotherapy for localized prostate cancer

被引:24
|
作者
Dess, Robert T. [1 ]
Hartman, Holly E. [2 ]
Aghdam, Nima [5 ]
Jackson, William C. [1 ]
Soni, Payal D. [1 ]
Abugharib, Ahmed E. [1 ]
Suy, Simeng [5 ]
Desai, Neil B. [6 ]
Zumsteg, Zachary S. [7 ]
Mehra, Rohit [3 ]
Morgan, Todd M. [4 ]
Feng, Felix Y. [8 ]
Hamstra, Daniel A. [9 ]
Schipper, Matthew J. [2 ]
Collins, Sean P. [5 ]
Spratt, Daniel E. [1 ]
机构
[1] Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA
[3] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA
[4] Univ Michigan, Dept Urol, Ann Arbor, MI 48109 USA
[5] Georgetown Univ, Dept Radiat Oncol, Washington, DC USA
[6] Univ Texas Southwestern, Dept Radiat Oncol, Dallas, TX USA
[7] Cedars Sinai, Dept Radiat Oncol, Los Angeles, CA USA
[8] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA USA
[9] Beaumont Hlth Syst, Dept Radiat Oncol, Dearborn, MI USA
关键词
erectile function; patient-reported outcomes; SBRT; sexual function; stereotactic body radiation therapy; #ProstateCancer; #PCSM; QUALITY-OF-LIFE; PATIENT-REPORTED OUTCOMES; RADIATION-THERAPY; RADICAL PROSTATECTOMY; ASSOCIATION; DYSFUNCTION; VERSION; COSTS; INDEX; MEN;
D O I
10.1111/bju.13962
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
ObjectiveTo elucidate the functional erection rate after prostate stereotactic body radiotherapy (SBRT) and to develop a comprehensive prognostic model of outcomes after treatment. Patients and MethodsBetween 2008 and 2013, 373 consecutive men with localized prostate cancer were treated with SBRT at a single academic institution as part of a prospective clinical trial or prospective registry. Prospective longitudinal patient-reported health-related quality of life (HRQoL) data was collected using the Expanded Prostate Cancer Index Composite (EPIC)-26 instrument. Functional erections were strictly defined as firm enough for intercourse' according to EPIC-26. Detailed comorbidity data were also collected. Logistic regression models were used to predict 24- and 60-month functional erection rates. Observed erection rates after SBRT were compared with those after other radiation therapies (external beam radiation therapy [EBRT] and brachytherapy) using prospectively validated models. ResultsThe median (interquartile range) follow-up was 56 (37-73) months and the response rate at 2years was 84%. For those with functional erections at baseline, 57% and 45% retained function at 24 and 60months, respectively. On multivariable analysis for 24-month erectile function, significant variables included higher baseline sexual HRQoL (adjusted odds ratio [aOR] 1.55 per 10 points, 95% confidence interval [CI] 1.37-1.74; P < 0.001) and older age (aOR 0.66 per 10 years, 95% CI 0.43-1.00; P = 0.05). At 60months, baseline HRQoL and age remained associated with erectile function, along with body mass index (aOR 0.45, 95% CI 0.26-0.78; P < 0.001). The 24- and 60-month models had excellent discrimination (c-index 0.81 and 0.84, respectively). Erection rates after SBRT were not statistically different from model-predicted rates after EBRT or brachytherapy for the whole cohort and the cohort with baseline erectile function. ConclusionsIntermediate- to long-term post-SBRT erectile function results are promising and not significantly different from other radiotherapy techniques. Clinicians can use our prognostic model to counsel patients regarding expected erectile function after SBRT.
引用
收藏
页码:61 / 68
页数:8
相关论文
共 50 条
  • [21] Prospective Randomized Phase II Study of Stereotactic Body Radiotherapy (SBRT) vs. Conventional Fractionated Radiotherapy (CFRT) for Chinese Patients with Early-Stage Localized Prostate Cancer
    Poon, Darren M. C.
    Lam, Daisy
    Wong, Kenneth C. W.
    Chu, Cheuk-Man
    Cheung, Michael
    Mo, Frankie
    Suen, Joyce
    Ng, Chi-Fai
    Chan, Anthony T. C.
    CURRENT ONCOLOGY, 2022, 29 (01) : 27 - 37
  • [22] Stereotactic body radiotherapy with periprostatic hydrogel spacer for localized prostate cancer: toxicity profile and early oncologic outcomes
    Hwang, Mark E.
    Mayeda, Mark
    Liz, Maria
    Goode-Marshall, Brenda
    Gonzalez, Lissette
    Elliston, Carl D.
    Spina, Catherine S.
    Padilla, Oscar A.
    Wenske, Sven
    Deutsch, Israel
    RADIATION ONCOLOGY, 2019, 14 (01)
  • [23] Prostate-specific antigen kinetics after stereotactic body radiotherapy for localized prostate cancer: A scoping review and meta-analysis
    Dejonckheere, Cas Stefaan
    Caglayan, Lara
    Glasmacher, Andrea Renate
    Wiegreffe, Shari
    Layer, Julian Philipp
    Nour, Youness
    Scafa, Davide
    Sarria, Gustavo Renato
    Spohn, Simon
    Essler, Markus
    Hauser, Stefan
    Ritter, Manuel
    Bernhardt, Marit
    Kristiansen, Glen
    Grosu, Anca-Ligia
    Zamboglou, Constantinos
    Gkika, Eleni
    RADIOTHERAPY AND ONCOLOGY, 2025, 202
  • [24] Stereotactic body radiotherapy (SBRT) as a treatment for localized prostate cancer: a retrospective analysis
    De Cooman, Brecht
    Debacker, Tibaut
    Adams, Thomas
    Lamberts, Guy
    De Troyer, Bart
    Claessens, Marc
    De Kerf, Geert
    Mercier, Carole
    Dirix, Piet
    Ost, Piet
    RADIATION ONCOLOGY, 2025, 20 (01)
  • [25] Erectile Dysfunction After External Beam Radiotherapy for Prostate Cancer
    Pinkawa, Michael
    Gagel, Bernd
    Piroth, Marc D.
    Fischedick, Karin
    Asadpour, Branka
    Kehl, Mareike
    Klotz, Jens
    Eble, Michael J.
    EUROPEAN UROLOGY, 2009, 55 (01) : 227 - 236
  • [26] Stereotactic Body Radiotherapy for Prostate Cancer
    Henderson, D. R.
    Tree, A. C.
    van As, N. J.
    CLINICAL ONCOLOGY, 2015, 27 (05) : 270 - 279
  • [27] Stereotactic Body Radiotherapy for Localized Kidney Cancer
    Benjamin J. Rich
    Miguel Angel Noy
    Alan Dal Pra
    Current Urology Reports, 2022, 23 : 371 - 381
  • [28] Stereotactic Body Radiotherapy for Localized Kidney Cancer
    Rich, Benjamin J.
    Noy, Miguel Angel
    Dal Pra, Alan
    CURRENT UROLOGY REPORTS, 2022, 23 (12) : 371 - 381
  • [29] Prostate-specific antigen kinetics after hypofractionated stereotactic body radiotherapy for localized prostate cancer
    Kim, H. J.
    Phak, J. H.
    Kim, W. Ch.
    INTERNATIONAL JOURNAL OF RADIATION RESEARCH, 2016, 14 (04): : 297 - 303
  • [30] Stereotactic Body Radiotherapy as Boost for Organ-confined Prostate Cancer
    Katz, Alan J.
    Santoro, Michael
    Ashley, Richard
    Diblasio, Ferdinand
    Witten, Matthew
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2010, 9 (06) : 575 - 582